Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07139912

Prospective, Multicenter, Single-Arm Study of Aortic Arch Pathology Reconstruction

A prospective ,multiple center Study about the Safety and Efficacy of the Thoracic Aortic Multi-Branch Stent Graft System, developed and manufactured by Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., in patients with aortic arch pathologies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 80 years
  • Diagnosed with aortic arch pathology requiring intervention, including:

True aortic arch aneurysm

Pseudoaneurysm of the aortic arch

Penetrating aortic ulcer involving the arch

  • Deemed suitable for endovascular repair by the investigating physician
  • Capable of understanding study objectives, providing written informed consent, and complying with follow-up requirements
  • Anatomic suitability confirmed by CTA:

Ascending aortic length ≥50 mm

Ascending aortic diameter ≥26 mm and ≤46 mm

Proximal landing zone length ≥20 mm

Brachiocephalic trunk diameter ≥9 mm and ≤19 mm with length ≥20 mm

Left common carotid artery (LCCA) and left subclavian artery (LSA) diameters ≥5 mm and ≤13 mm

LCCA length ≥20 mm

Distance from LSA ostium to left vertebral artery origin ≥20 mm

  • High surgical risk per investigator assessment OR contraindicated for open surgery

Exclusion criteria

  • Pregnant or lactating women
  • Connective tissue disorders affecting the aorta (e.g., Marfan syndrome, Ehlers-Danlos syndrome)
  • Infected aortic pathologies or aortitis (e.g., mycotic aneurysm, Takayasu arteritis)
  • Prior endovascular repair of ascending aorta/aortic arch
  • Documented allergy to nitinol, contrast media, or device materials
  • Severe renal impairment:(Serum creatinine >2×ULN,Excluding dialysis-dependent patients)
  • Hematologic abnormalities:(WBC <3×10⁹/L、Hb <70 g/L、PLT <50×10⁹/L)
  • Heart transplant recipients
  • Myocardial infarction or stroke within 3 months
  • NYHA Class IV heart failure
  • Active systemic infection (e.g., bacteremia, sepsis)
  • Life expectancy <12 months
  • Mechanical aortic valve prosthesis impeding device delivery
  • Current participation in other interventional trials with primary endpoint pending
  • Anticipated poor compliance with follow-up
  • Other contraindications for endovascular repair per investigator assessment:Severe vascular stenosis/calcification/tortuosity/Thrombus at landing zones/Inability to cooperate with procedure

Treatment and study plan

Thoracic Aortic Multi-Branch Stent Graft System

Device

The Thoracic Aortic Multi-Branch Stent Graft Systemm consists of the Single-Branch Aortic Stent-Graft System, the aortic extension stent graft system and the branch stent system.

Primary outcomes

  1. 12-month treatment success rate

    Time frame: 12-month

    Technical success at the index procedure, without device- or aortic pathology-related mortality or unplanned secondary interventions, and with no evidence of persistent enlargement of the treated aortic segment due to Type I/III endoleaks on 12-month CTA follow-up.

  2. 30-day rate of Major Adverse Events (MAE)

    Time frame: 30-day

    Including all-cause mortality, disabling stroke, persistent paraplegia, renal failure, myocardial infarction, and respiratory failure

Study contacts

Contact information is provided by the study sponsor or research team.

Qingsheng Lu

CONTACT

[email protected]

021-31162185

Sponsors and collaborators

Lead sponsor

Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd

Industry

Registry information

Official study title

Prospective, Multicenter, Single-Arm Trial Assessing Safety/Effectiveness of Multi-Branch Thoracic Stent Grafts in Aortic Arch Disease

Important dates

Study start
2025
Primary completion
2028
Study completion
2032
First posted
Aug 24, 2025
Registry last updated
Aug 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.